Want to see IRIX full AI Analyst Report?
IRIX Stock Chart & Stats
$1.23
-$0.02(-1.39%)
At close: 4:00 PM EST
$1.23
-$0.02(-1.39%)
Day’s Range― - ―
52-Week Range$0.87 - $1.65
Previous CloseN/A
Volume8.51K
Average Volume (3M)66.91K
Market Cap
$16.11M
Enterprise Value$22.65
Total Cash (Recent Filing)$4.59M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding17,406,519
10 Day Avg. Volume69,445
30 Day Avg. Volume66,914
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.09
Price to Sales (P/S)0.38
P/FCF Ratio-8.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.75Price Target Upside123.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$53.00M
Bulls Say, Bears Say
Bulls Say
Installed-base Recurring Consumables RevenueIridex generates repeatable revenue from single-use delivery devices and procedure consumables tied to its installed laser base. This installed-base-driven recurring stream supports revenue visibility, higher lifetime customer value, and more predictable cash flow than one-time capital sales alone.
G‑Probe And Cyclo G6 Product MomentumSustained unit growth in probes and mid-single-digit to double-digit product revenue growth demonstrate commercial traction for core therapies. Durable demand for consumable probes and growing Cyclo G6 placements support recurring revenue and strengthen Iridex's position in glaucoma and retina treatment markets.
Margin And Cost-structure Improvement InitiativesMulti-quarter actions—G&A relocation delivering near-term savings and a planned contract-manufacturing shift—are structural levers to improve gross margins and lower fixed costs. If executed, these moves can sustainably reduce burn and raise operating leverage as revenue stabilizes.
Bears Say
Revenue Contraction And Compressed Gross MarginsAn 18% TTM revenue decline and materially lower gross margins reflect weakening top-line and margin pressure from mix, costs, or pricing. These trends reduce operating leverage and mean the business must restore volume or materially improve margins to return to sustained profitability.
Negative Operating And Free Cash Flow With Small Cash CushionPersistent negative operating and free cash flow indicate the core business still consumes cash despite improvement. A modest quarter-end cash balance heightens funding risk, making the firm sensitive to execution delays, slower sales, or unexpected costs absent external financing or rapid margin gains.
Governance And Shareholder Control RiskAn active shareholder campaign, a large disclosed stake and board investigation create a structural governance overhang. This raises the risk of strategic disruption, potential governance litigation or dilutive proposals, and management distraction that can impede long-term execution and capital decisions.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.87 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $16.11M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Iridex Corp’s earnings last quarter?
Iridex Corp released its earnings results on May 19, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.04.
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate is -0.01.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,406,519 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Iridex Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
IRIX Stock 12 Month Forecast
Average Price Target
$2.75
▲(123.58% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
11.73% Insiders
3.60% Mutual Funds
8.02% Other Institutional Investors
73.69% Public Companies and
Individual Investors